Published in J Hepatol on August 01, 2005
Stem cell-based therapies for liver diseases: state of the art and new perspectives. Stem Cells Int (2010) 0.88
Stem cells, a two-edged sword: risks and potentials of regenerative medicine. World J Gastroenterol (2008) 0.82
Ultrasound-guided percutaneous portal transplantation of peripheral blood monocytes in patients with liver cirrhosis. Korean J Intern Med (2016) 0.75
Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann Intern Med (2008) 3.54
Dual role of CCR2 in the constitution and the resolution of liver fibrosis in mice. Am J Pathol (2009) 1.49
Bone marrow transplantation in mice leads to a minor population of hepatocytes that can be selectively amplified in vivo. Hepatology (2002) 1.17
Conditional cell ablation by tight control of caspase-3 dimerization in transgenic mice. Nat Biotechnol (2002) 1.11
Combined hepatocellular-cholangiocarcinomas exhibit progenitor features and activation of Wnt and TGFβ signaling pathways. Carcinogenesis (2012) 0.95
Protection against hepatocyte mitochondrial dysfunction delays fibrosis progression in mice. Am J Pathol (2009) 0.90
Transient micro-elastography: A novel non-invasive approach to measure liver stiffness in mice. World J Gastroenterol (2011) 0.90
The combination of ischemic preconditioning and liver Bcl-2 overexpression is a suitable strategy to prevent liver and lung damage after hepatic ischemia-reperfusion. Am J Pathol (2002) 0.88
GH receptor plays a major role in liver regeneration through the control of EGFR and ERK1/2 activation. Endocrinology (2011) 0.86
Risk factors for post-ICU red blood cell transfusion: a prospective study. Crit Care (2006) 0.84
Increased susceptibility to liver fibrosis with age is correlated with an altered inflammatory response. Rejuvenation Res (2011) 0.84
EGFR: A Master Piece in G1/S Phase Transition of Liver Regeneration. Int J Hepatol (2012) 0.84
Delayed liver regeneration in mice lacking liver serum response factor. Am J Physiol Gastrointest Liver Physiol (2006) 0.83
Mesenchymal stem cells: an alternative source of hepatocytes? Hepatology (2004) 0.81
[Humanized mice for the study of hepatitis C]. Med Sci (Paris) (2011) 0.81
[IL28 (interferon lambda3) gene polymorphisms and response to IFN-alpha treatment in patients infected with hepatitis virus C]. Med Sci (Paris) (2010) 0.81
Liver repopulation by Bcl-x(L) transgenic hepatocytes. Am J Pathol (2002) 0.80
Overexpression of Bcl-2 in hepatocytes protects against injury but does not attenuate fibrosis in a mouse model of chronic cholestatic liver disease. Lab Invest (2010) 0.79
GH administration rescues fatty liver regeneration impairment by restoring GH/EGFR pathway deficiency. Endocrinology (2014) 0.78
[Transplantation of isolated hepatocytes. Principles, mechanisms, animal models, clinical results]. Gastroenterol Clin Biol (2002) 0.77
[Liver repopulation: the selective advantage concept]. Gastroenterol Clin Biol (2002) 0.76
Had Prometheus known, would he have preferred to be obese? J Gastroenterol Hepatol (2007) 0.75
[Decline of liver'age-dependent regenerative capacities: some molecular tracks]. Med Sci (Paris) (2007) 0.75
[Hippo-YAP signaling pathway in the liver: more than a size gatekeeper!]. Med Sci (Paris) (2011) 0.75
[Facio-scapulo-humeral myopathy: a repression defect?]. Med Sci (Paris) (2003) 0.75
[Is reprogramming of carcinoma cells possible?]. Med Sci (Paris) (2005) 0.75
[Hepatic stem cells: it's quite an undertaking!]. Med Sci (Paris) (2004) 0.75
[Sirtuin 1, hepatic steatosis and liver cancer]. Med Sci (Paris) (2012) 0.75
[Liver repopulation strategies]. Bull Acad Natl Med (2005) 0.75
[Experimental modulation of apoptosis: physiopathological and therapeutic targets]. J Soc Biol (2005) 0.75